MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer

Loss of cell cycle control is a hallmark of cancer, which can be targeted with agents, including Cyclin Dependent Kinase-4/6 (CDK4/6) kinase inhibitors that impinge upon the G1-S cell cycle checkpoint via maintaining activity of the retinoblastoma tumor suppressor (RB). This class of drugs is under...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: de Leeuw, Renée, McNair, Christopher M., Schiewer, Matthew J., Neupane, Neermala Poudel, Brand, Lucas J., Augello, Michael A., Li, Zhen, Cheng, Larry C., Yoshida, Akihiro, Courtney, Sean M., Hazard, E. Starr, Hardiman, Gary, Hussain, Maha H., Diehl, J. Alan, Drake, Justin M., Kelly, Wm. Kevin, Knudsen, Karen E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6125187/
https://ncbi.nlm.nih.gov/pubmed/29739788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0410
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares